Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436031 · ClinicalTrials.gov registry record · Phase 2
Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B
A Phase 2 study of Sleep Apnea, Obstructive, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02436031 is a Phase 2 study of Sleep Apnea, Obstructive that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 16 participants, below the 262-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02436031, a Phase 2 study of Sleep Apnea, Obstructive, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on upper airway collapsibility and genioglossus muscle activity (EMG GG) during sleep in OSA patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Desipramine
Study Locations (1)
Massachusetts
- Sleep Disorders Research Program Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02436031
The ClinicalTrials.gov registry entry for NCT02436031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (94% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sleep Apnea, Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02436031 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02436031 about?
NCT02436031 is a clinical study titled "Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B". Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. U...
What is the current status of trial NCT02436031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-04. Estimated completion is 2016-03.
What conditions does trial NCT02436031 study?
This clinical trial studies the following conditions: Sleep Apnea, Obstructive.
What interventions are being tested in trial NCT02436031?
The interventions under investigation include: Placebo (DRUG), Desipramine (DRUG).
Who is sponsoring clinical trial NCT02436031?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02436031 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Apnea, Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Do Endotypes Predict Response and Sequelae in OSA Patients
RECRUITING · Phase 2
-
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
RECRUITING · Phase 2
-
Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea
COMPLETED · Phase 2
-
Nasal vs Oral Breathing in Drug Induced Sleep vs Natural Sleep
RECRUITING
-
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
RECRUITING · NA
-
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.